Decision-making Processes Regarding Cancer Technologies: A Review
Notice bibliographique
Résumé
The issue of timely access to high quality cancer care has heightened in Canada, fueled in part by incidence rates reaching levels where cancer now touches, in some way, the lives of most Canadians. (1) Thus, deliberations over how best to maximize the health of cancer patients are often emotionally and politically charged. Two major issues have been highlighted through the media and the political process: (1) timely access to required services (i.e., waiting times for radiation, surgery and specialist consultation), (2) limits placed on equitable access to services such as diagnostic interventions (e.g., MRI and PET) and (3) cancer drug treatments. As cancer agencies across the country look for ways to provide timely access to technologies that deliver high quality care, they do so facing unlimited demands, limited budgets, and intense scrutiny by both those affected and the media. There seems to be a growing lack of public confidence in decisions about which technologies to publicly fund, particularly in the case of promising, often high cost innovations championed by physicians, patients and manufacturers. As a result, policy-makers charged with the task of ensuring prudent and principled use of scarce resources have become demonized, since the essence of priority-setting means that access to some will be denied. It has become increasingly clear that approaches to priority-setting require a blending of two decisional domains: effectiveness and efficiency (the evidence-based paradigm) and equity/fairness (the values/ethics based paradigm). What remains unclear are ways of marrying the two so that coverage decisions may be deemed legitimate and fair by all stakeholders. Over the past three decades, an international body of work focusing on resource allocation and technology funding decision-making has emerged in response to the increasing pressures faced by governments to adopt new and innovative technologies into their health care systems. (2) It contains research which draws from many disciplines including: clinical medicine; epidemiology; political, social, behavioral and management sciences; economics; and ethics. This work examines how decisions are actually made (i.e., descriptive processes), how they should be made (i.e., normative processes), and tools for aiding or informing these processes. (3) While the majority of this work has taken place outside of the cancer context, it addresses issues of a similar nature and complexity. This paper provides an overview of this work to inform both scholars (in ethics, law and health services research) and decision-makers in Canadian health care systems. Descriptive Processes Canadian research describing how funding recommendations or decisions for new cancer technologies are actually made is limited to a few case studies in Ontario. (4) Factors shaping decisions were identified through a combination of document analysis, interviews of Cancer Care Ontario's Policy Advisory Committee, and observations of their meetings. These factors included: benefit to patients and its magnitude, quality of evidence (i.e., the degree of certainty of the benefit), existence of alternatives, treatment duration, total population of patients affected, total cost to the system, pressure from physician and patient groups, and historical precedent. Cost-effectiveness was not used, but the committee discussed the concept of value-for-money. Although the committee had initially considered developing a list of funding recommendations, ranking them, comparing the costs against a known fixed budget, and then drawing a line at the end of the resources, it abandoned the idea when members failed to agree upon potential priority measures. (5) A similar study was conducted in the United Kingdom, where a specialist cancer hospital and a consortium of six regional health authorities set priorities for funding new drugs. …
Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.
Comment cette classification a été obtenuedéplier
Prédiction distillée sur la base complète
Imitation des enseignantsNi prévalence calibrée, ni vérité terrain. Validation humaine à venir. Apprise à partir de 10 348 étiquettes directes de Codex et de 10 348 étiquettes directes de Gemma. Le mode candidate est l'union des têtes enseignantes seuillées; le consensus est leur intersection. Ces sorties portent le statut machine_predicted_unvalidated et ne sont ni des étiquettes humaines ni des étiquettes directes de modèles de pointe.
Scores Codex et Gemma par catégorie
| Catégorie | Codex | Gemma |
|---|---|---|
| Métarecherche | 0,002 | 0,008 |
| Méta-épidémiologie (sens strict) | 0,001 | 0,002 |
| Méta-épidémiologie (sens large) | 0,007 | 0,001 |
| Bibliométrie | 0,002 | 0,004 |
| Études des sciences et des technologies | 0,001 | 0,000 |
| Communication savante | 0,000 | 0,005 |
| Science ouverte | 0,003 | 0,001 |
| Intégrité de la recherche | 0,001 | 0,001 |
| Charge utile insuffisante (le modèle a refusé de juger) | 0,001 | 0,003 |
Scores machine (provisoires)
Les deux têtes enseignantes du modèle étudiant, lues sur ce travail. Un score ordonne la base pour la relecture; il n'affirme jamais une catégorie, et le statut de validation accompagne chaque rangée tel quel.
Scores de référence d'un modèle non mature (critères de maturité non atteints, 7 itérations). Un score ordonne; il n'affirme jamais une catégorie.
score_only:v0-immature-baseline · tel quel depuis la passe de notation : score_only signifie que le nombre peut ordonner les travaux, et qu'aucune étiquette de catégorie n'en découleClassification
machine, non validéePrédiction automatique; les deux têtes enseignantes s’accordent sur ce qui est montré ici.
Le détail, modèle par modèle et score par score, se trouve en fin de page sous « Comment cette classification a été obtenue ».